In the release, INO said that the flu vaccine provides 100% protection against lethal challenge in the gold standard ferret model. The company also said that preclinical flu vaccine study results were detailed in a paper that was published in the journal Vaccine. The paper was titled Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. In a statement, Dr. Laurent Humeau, Senior Vice President of Research and Development at INO, had the following to offer:
Funded by a grant from the N1H, this published work demonstrates that Inovio’s ASPIRETM (Antigen SPecific Immune REsponses) technology platform could produce a universal flu vaccine that can span seasonal vaccine changes allowing for continued immune protection. We are proud to advance Inovio technology and contribute to advanced cutting edge technology for the important global health treats. These studies also showcase the latest CELLECTRA intradermal (skin) delivery system to facilitate optimal antigen production and generation of superior immune responses in animal models.
What We’re Seeing From The Stock
As investors, one of the first things that we learn is that the news moves the market. In this particular case, the news released by Inovio Pharmaceuticals surrounded strong clinical prospects, leading to excitement among investors and gains in the value of the stock. Of course, our partners at Trade Ideas were the first to alert us to the gains. Currently (10:45), INO is trading at $5.06 per share after a gain of $0.41 per share (8.94%) thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on INO. In particular, we’re interested in following the continued work with regard to flu vaccinations and excited to see future results as development continues. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!